Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Mereo BioPharma Group plc (MREO)

Core Viewpoint - A securities class action lawsuit has been filed against Mereo BioPharma Group plc for allegedly providing misleading statements regarding the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals or entities that purchased Mereo securities between June 5, 2023, and December 26, 2025 [1]. - The Complaint claims that Mereo's misleading statements led to shareholders purchasing its American Depositary Shares (ADS) at artificially inflated prices [2]. Group 2: Study Results - The Complaint alleges that the Phase 3 ORBIT and COSMIC studies failed to achieve statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonate control groups [2][3]. - Despite improvements in bone mineral density, neither study met its primary endpoint [3]. Group 3: Market Reaction - Following the announcement on December 29, 2025, that the studies did not meet their primary endpoints, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7% [4].